There are more than 1,400 listed clinical trials for macular degeneration

New eye implant clinical trial recruiting in 2026

University of Southern California researchers have launched a phase 2b clinical trial of a stem cell implant designed to restore vision in people with advanced dry macular degeneration. Patients will be randomized to receive the stem cell implant or a simulated procedure and placebo implant. This type of larger, second-stage clinical trial is designed to confirm efficacy and dosing and to look for side effects. It's one of the stages that precedes the US Food & Drug Administration approval of a device.

US macular degeneration burden is based on statistical modeling and Medicare claims

Prevalence estimates for age-related macular degeneration in the US are usually based on the Vision and Eye Health Surveillance System. Disease numbers are generated using Bayesian meta-regression (a type of statistical modeling), which pulls together information from multiple sources, including Medicare claims.

World health experts expect more than 240 million global cases of AMD in 2030

The World Health Organization estimated in 2019 that by 2020 there would be roughly 195.6 million cases of age-related macular degeneration and projected that the number would continue to grow. (Some users may experience a paywall.)

Wet macular degeneration affects 10%-15% of those with macular degeneration

This form of molecular degeneration refers to when excess blood vessels form in the back of the eye and damage the macula. If someone with this condition looks at straight lines, they will typically appear wavy or crooked.

Age-related macular degeneration is the primary cause of blindness in older Americans.

In a first, eye prosthesis has restored sight to macular generation patients

In a clinical trial, 27 of 32 participants with advanced macular degeneration regained enough vision to read books, food labels, and subway signs about a year after receiving a prosthetic retina device. This is the first device to restore functional vision to patients with incurable vision loss, though in this case they can only see in black and white, with no shades in between.

Watch patient stories describing life with macular degeneration

This video series features patients discussing their experiences with the disorder, family members describing caregiving, and other insights about the disease.

As of February 2025, there are more than 150 clinical trials using CRISPR technology

The clinical trials are designed to determine whether experimental CRISPR-related therapies are safe and effective. The majority of trials involve treatments for blood disorders, including beta thalassemia.

Photodynamic therapy is one current treatment for age-related macular degeneration.

Targeting cholesterol metabolism may help address macular degeneration.

Caucasians are at the greatest risk of developing macular degeneration

A 2016 analysis across ethnic groups found, among other things, that white participants had the highest incidence of the disease, followed by Chinese, Hispanic, and Black participants. This study did not answer why that may be the case.

Vitamins can slow macular degeneration

Research published in 2022 affirmed that vitamin formulations containing vitamins C and E, copper, zinc, lutein, and zeaxanthin—but no beta carotene—can enhance eye health and slow the progression of macular degeneration.

As deposits build up under the eye, the retina bends with macular degeneration

The retina bends due to the accumulation of proteins and other materials beneath it. That's considered the milder "dry" form of macular degeneration. Another form, called "wet" macular degeneration, is caused by abnormal blood vessels leaking fluid into the eye, which can rapidly affect central vision.

Drusen are bumps under the retina that distort the vision of most macular degeneration patients

These yellow deposits are made up of proteins and lipids and come in a variety of sizes. They're common in people aged 50 and older, but amassing many of them is often a symptom of age-related macular degeneration—the most prevalent type of macular degeneration.

The macula is a small area in the center of the retina

This part of the eye—roughly the bullseye of the back of the eye—is responsible for processing the central vision of the eye. Degradation of the macula, formally called macular degeneration, leads to symptoms including blurred vision, the need for brighter lighting, and difficulty recognizing faces. The condition doesn't affect peripheral vision, but if you lose central vision, you can still be considered blind.

People with blue eyes appear to be at elevated risk of developing macular degeneration, perhaps because more light can penetrate their eyes.

More than 200 drug trials for Alzheimer's have failed or been abandoned since 2010, but two anti-amyloid infusion medications have netted FDA approval in recent years.

Scientists using gene therapy recently managed to regenerate retinal cells in the lab—a breakthrough for mammals that could potentially lead to future treatments for human retinal diseases.

See the global blindness burden by cause and continent.

Dozens of US research projects focus on the zebrafish's ability to grow new retina cells

The small, striped minnow can repair its optic nerve in just under a week. Scientists are interested in hacking its regenerative capacity to grow new retina cells to treat human eye disorders, including macular degeneration. In 2020, the US National Eye Institute had nearly 80 projects focused on zebrafish.

Minorities are largely underrepresented in medical research, which compromises our understanding of how conditions and treatments may affect various populations, but recent efforts, like the African Ancestry Neuroscience Research Initiative and new genome research studies, are seeking to close that gap.

Late-stage clinical trials indicate that a common arthritis drug may be a promising treatment for a leading cause of hair loss.

A new daily MS pill is seeking regulatory approval in 2026

In clinical trials, Roche's fenebrutinib showed promise treating primary progressive MS and doubling relapse-free time in patients with relapsing MS as compared to existing treatment. But some liver damage and two possible drug-related deaths in the trials may make it difficult for the drug to net approval. (Some users may encounter a paywall.)

A planned clinical trial to treat a rare lysosomal storage disorder in utero has buoyed hopes of providing prenatal gene therapies, but it was still awaiting FDA approval to begin enrolling patients as of May 2026.

A snapshot of progress in cancer treatments

The American Association for Cancer Research's "Snapshot of a Year of Progress" offers an overview of significant advancements in cancer research and treatment over the past year. Take a quick look at the rapid pace of scientific discovery and the translation of research findings into clinical practice. In 2024 alone, health regulators approved 15 new anticancer therapies alone.

The US FDA considered mitochondrial replacement therapy during 2014 hearings

An agency committee assessed if this approach could have undesirable ripple effects across multiple generations and whether a clinical trial involving this approach would be appropriate. As of 2026, the US has continued to prohibit this procedure though it is legal in other settings including the UK and Australia.

Using brain implants to restore vision

Several companies are attempting to create brain-computer interfaces that skip over retinas and optic nerves to allow visual input to go straight to the brain, potentially restoring some sight to the blind. Clinical trial findings suggest restored sight is sparse and manifests differently than a sighted person might expect, appearing as specks of "light" clusters called phosphenes to help differentiate one's surroundings.

A 1974 Science News article proclaimed that within a decade, light therapy would be on par with traditional drugs.

A physician with a rare and deadly disease saved his own life by identifying an existing medication that he repurposed for his condition, and now he's using AI to try to do the same for other patients.

A clinical trial is underway in 2026 to help kidney transplant recipients avoid a lifetime of immunosuppressing drugs

This later-stage clinical trial, in Chicago and Taiwan, evaluates the efficacy and safety of a new cellular therapy that may be swapped in for immunosuppressing drugs among kidney transplant recipients. The study randomizes people to either receive standard immunosuppressants or this cellular therapy and fewer immunosuppressants. It only includes kidney transplant recipients receiving organs from live donors so transplant surgery timing won't hinge on the unpredictable schedule of performing surgery and follow-up care when a donor dies.

How MS is diagnosed with brain and spinal cord MRIs and eye tests

There's no definitive test for MS, but to make a diagnosis doctors typically use MRIs of the brain and spinal cord to hunt for telltale lesions. Also, optic nerve tests to see how quickly information travels down the optic nerve—since degraded myelin sheaths will slow electrical signals between the eye and brain.

Roughly 1 in every 4,300 individuals in the US has mitochondrial disease

Roughly 1,000 to 4,000 kids are born with these conditions each year in the US though many of the diseases are fatal. Mitochondrial disorders often affect the organs that require the most energy, including the heart, brain, and muscles.

Restoring vision in impaired patients via CRISPR

Since CRISPR was revealed as a gene editing tool in 2012, it has been on an accelerated track to real-world applications. Among other clinical demonstrations, doctors have now injected a CRISPR treatment directly into eye cells, helping vision-impaired patients see shapes and colors again.

Five advancements in arthritis research

It is estimated that nearly 350 million people worldwide are currently suffering from arthritis. This resource explores five of the most promising recent advancements in arthritis research as scientists work towards improved treatments and continue the search for a cure.

More than 5 million Americans have more than one autoimmune disease

Overall, about 4.6% of the US population—15 million people—have an autoimmune condition. Some common examples include rheumatoid arthritis, psoriasis, type 1 diabetes, Grave's disease, and autoimmune thyroiditis.

No one is tracking the total number of animals used for research across US labs, though partial data without any rodents puts the 2024 count above 775,000 animals, including some 40,000 dogs and 100,000 primates.

86 commonly used drugs, including certain antidepressants, painkillers, and immunosuppressants, have different results for men and women, according to recent research.

US depression rates at historic high among adults

More than 18% of US adults reported that they currently have or are being treated for depression in both 2024 and 2025. In the 2025 survey, more than 11,000 adults were surveyed. The numbers have ticked upward since 2015—by about 8 percentage points—with most of the increase occurring from the 2020 pandemic onward.

The lack of diversity in clinical trials is undermining the future of precision medicine

Medicine works better when the treatments are tailored to fit each individual person’s biology and history. Homogeneous patient selection in clinical trials means treatments and care are being refined based on only a small range of variables, some of which may not apply to you. This 40-minute podcast episode discusses the historical and current reasons for the lack of clinical trial diversity and what this means for the future of personalized medicine.

Females are diagnosed with MS roughly 3 to 4 times more often than males

This PBS documentary traces a filmmaker's personal journey with MS after being diagnosed at age 26. It encompasses both his efforts to stymie the disease's progression and his search for answers about the disease, when, statistically, he seemed at low risk due to his gender, lack of known family risk, and other factors.

There are two FDA-approved blood tests that may detect early Alzheimer's disease.

Read a study about racial differences in Lyme disease diagnosis

The research published in September 2025 examined differences in Lyme disease diagnosis among Medicaid and Medicare beneficiaries using data from 2016 to 2021. It notes that though US Lyme disease surveillance data indicates more than 90% of diagnosed Lyme cases are among white people, people of color—particularly those who identify as Black or African American—have higher rates of more severe disease of Lyme, with symptoms including arthritis and neurologic impacts.

It's been about 30 years since a new hair loss drug was approved in the US, and women currently have no approved pills for hair loss.

Learn about the more than 100 known autoimmune diseases

Explore this resource with summaries and related resources for the dozens of autoimmune diseases defined in the medical literature. Many of these disease write-ups also have interviews with a patient with the disorder—offering a personal take about challenges, advice, and lifestyle effects.

Support groups can offer insights into current and potential treatments

Beyond connecting with patients with similar experiences, support groups can also become centers for advocacy and for sharing research advances and medical experiences, including potential side effects from novel therapies or clinical trials.

1 in 10 US adults are taking medication for depression

A US government report indicates that about 10% of US adults took prescription medication for this disorder in 2023. Women, at 15.3%, were more than twice as likely to take one of these medications than the 7.4% of men.

See this list of FDA-approved gene therapies, including offerings for inherited conditions as well as some forms of cancer.

US regulators have approved an at-home genetic test looking for BRCA gene mutations

The direct-to-consumer genetic test, approved by US regulators in 2018, examines 3 out of the more than 1,000 known breast cancer-linked genetic mutations. It looks for genetic variations that can increase risk for breast, ovarian, and other cancers. These mutations are most commonly found among Jewish people with Eastern European ancestry.

Remylination is a huge focus for treatment—especially among older adults

Our ability to build new myelin sheaths for nerves degrades with age. There have been research advances boosting cells that support these processes and clear away debris from degraded myelin, but not yet any medications to boost myelination itself, which would aid nerve signaling and preserve nerve function.

Explore this database to discover Lyme disease incidence in your county.